An open label study to evaluate the effect of PEGASYS [peginterferon alfa-2a] on ALT [alanine transminase] and HBV [hepatitis-B virus] DNA levels in patients with lamivudine-resistant HbeAg-negative chronic hepatitis B.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2010

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary)
Indications Hepatitis B
Focus Therapeutic Use
Sponsors Roche

Most Recent Events

30 Jun 2008 Status changed from recruiting to discontinued, as reported by Roche.
22 Oct 2007 Status changed from initiated to recruiting
29 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight